Zena N. Willsmore

St. John's Institute Of Dermatology
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Circulating B cell and T cell activation states predict clinical outcomes in melanoma and reveal dynamic immune reinvigoration with checkpoint inhibitor immunotherapy.

Circulating B cell and T cell activation states predict clinical outcomes in melanoma and reveal dynamic immune reinvigoration with checkpoint inhibitor immunotherapy.

Journal: Journal for immunotherapy of cancer

Published: July 23, 2026

Circulating immunoregulatory B cell and autoreactive antibody profiles predict lack of toxicity to anti-PD-1 checkpoint inhibitor treatment in advanced melanoma.

Circulating immunoregulatory B cell and autoreactive antibody profiles predict lack of toxicity to anti-PD-1 checkpoint inhibitor treatment in advanced melanoma.

Journal: Journal for immunotherapy of cancer

Published: May 13, 2025

Non-Allergic Urticarial Skin Reactions Associated With MOv18 IgE, a First-In-Class IgE Antibody Recognising Folate Receptor Alpha.

Non-Allergic Urticarial Skin Reactions Associated With MOv18 IgE, a First-In-Class IgE Antibody Recognising Folate Receptor Alpha.

Journal: Allergy

Published: August 14, 2024

Tumor associated macrophages as key contributors and targets in current and future therapies for melanoma.

Tumor associated macrophages as key contributors and targets in current and future therapies for melanoma.

Journal: Expert review of clinical immunology

Published: March 27, 2024

Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies.

Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies.

Journal: Oncoimmunology

Published: October 10, 2022

Enriched circulating and tumor-resident TGF-β+ regulatory B cells in patients with melanoma promote FOXP3+ Tregs.

Enriched circulating and tumor-resident TGF-β+ regulatory B cells in patients with melanoma promote FOXP3+ Tregs.

Journal: Oncoimmunology

Published: August 01, 2022

B cell profiles, antibody repertoire and reactivity reveal dysregulated responses with autoimmune features in melanoma.

B cell profiles, antibody repertoire and reactivity reveal dysregulated responses with autoimmune features in melanoma.

Journal: Nature communications

Published: June 01, 2022

BRAF inhibitors and their immunological effects in malignant melanoma.

BRAF inhibitors and their immunological effects in malignant melanoma.

Journal: Expert review of clinical immunology

Published: February 23, 2022

Regulatory B cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade.

Regulatory B cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade.

Journal: Nature communications

Published: August 14, 2021

Follicular T-Helper Cells in Marginal Zone Lymphoma: Evidence of an Organoid Immune Response.

Follicular T-Helper Cells in Marginal Zone Lymphoma: Evidence of an Organoid Immune Response.

Journal: The American Journal of dermatopathology

Published: July 07, 2021

A Problem of Classification: 2 Cases of Epstein-Barr Virus + Primary Cutaneous Plasmacytoma Arising in Immunocompetent Elderly Patients.

A Problem of Classification: 2 Cases of Epstein-Barr Virus + Primary Cutaneous Plasmacytoma Arising in Immunocompetent Elderly Patients.

Journal: The American Journal of dermatopathology

Published: June 04, 2021

B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies.

B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies.

Journal: Frontiers in immunology

Published: October 28, 2020

Showing 1-12 of 13

Last Updated: 09/26/2026